As follow-up lengthens in a prospective, randomized, controlled trial, men who underwent bipolar plasma vaporization of the prostate for BPH using the “button” vapo-resection electrode continue to demonstrate significantly better symptom scores and voiding characteristics compared to their counterparts treated by bipolar transurethral resection in saline or monopolar transurethral resection of the prostate.
In the treatment of BPH, while both bipolar-transurethral resection of the prostate (B-TURP) and monopolar-TURP (M-TURP) have similar clinical efficacy, B-TURP is associated with fewer adverse events, according to a recent systematic review of the two modalities.
A minimally invasive implant procedure led to a 50% improvement in lower urinary tract symptoms due to BPH, which was maintained for a year, results of a randomized trial showed.
Drugs and devices in the pipeline from Targacept, Inc., Cubist, OncoGenex Pharmaceuticals, Inc., Apricus Biosciences, and Nymox Pharmaceutical Corp.
New products and services from GenomeDx Biosciences, the Coding Institute, Astellas Pharma US, Greenbranch Publishing, the National Association for Continence, Perrigo Co., the Bladder Cancer Advocacy Network, and the Brewer Co.
Bruce R. Kava, MD, presents the take home messages on BPH/LUTS from the AUA annual meeting in San Diego.
Priya Padmanabhan, MD, MPH, presents the take home messages on female urology/incontinence/urodynamics from the AUA annual meeting in San Diego.
Jeannette M. Potts, MD, presents the take home messages on infection and inflammation at the AUA annual meeting in San Diego.
Estrogen supplements may help menopausal women ward off recurrent urinary tract infections, researchers recently reported.
A generic version of the overactive bladder drug trospium chloride has received FDA approval and is now available.
The new-generation GreenLight XPS-180W laser system (American Medical Systems, Minnetonka, MN) achieved an improved rate of tissue vaporization and overall efficacy in patients with BPH compared to an earlier generation laser, according to results of a recent multicenter study.
In this case, the woman claimed her damages from the negligent nerve injury included pain and weakness in her legs and a second operation to replace the sling.
Data from a recent multicenter study provide new evidence that the beta-3 adrenoceptor agonist mirabegron (Myrbetriq) appears to be a viable alternative in patients with overactive bladder (OAB) who are poor responders to antimuscarinic agents or intolerant of their adverse events.
Men with symptomatic BPH had statistically significant, durable improvement in lower urinary tract symptoms (LUTS) following an office-based, minimally invasive prostatic urethral lift procedure, results of a pivotal randomized trial showed.
Building on previous research suggesting a cause-and-effect link between mental illness and urinary dysfunction, a new study finds that older men with two or more lower urinary tract symptoms are more likely to have recently had thoughts of suicide.
Stress incontinent women whose urinary urgency incontinence worsens following a sling procedure are a heterogeneous group, researchers report.
Mesh removal after suburethral sling procedures led to additional incontinence surgery in more than half of patients, including many who were continent prior to sling removal, a study of almost 100 patients showed.
In the area of female urology, look for key studies at the AUA annual meeting involving sling surgery, onabotulinumtoxinA (Botox) injections, and reoperation after pelvic organ prolapse surgery with mesh.
Data from a recent multicenter study provide new evidence that the beta-3 adrenoceptor agonist mirabegron (Myrbetriq) appears to be a viable alternative in patients with overactive bladder who are poor responders to antimuscarinic agents or intolerant of their adverse events.
THVD-201 (Tolenix), a novel formulation combining tolterodine and pilocarpine, was found safe, well tolerated, and effective against overactive bladder (OAB) in a recent study.
The algorithm for urologists’ approach to male voiding symptoms is evolving, according to Steven A. Kaplan, MD, of Weill Cornell Medical College, New York. This will be evident in presentations on BPH and lower urinary tract symptoms at the AUA annual meeting.
Men with BPH may obtain symptomatic relief with minimally invasive prostatic artery embolization (PAE), according to results from a small, prospective study.
A recent study highlights huge price swings in patient charges for the 10 most common outpatient conditions-including kidney stones and urinary tract infection-in emergency rooms across the country.
For women with uncomplicated, stress-predominant incontinence, urodynamic testing adds considerable expense without improving surgical outcomes, a recent trial shows.
Preoperative urodynamic testing in women undergoing surgery for uncomplicated, stress-predominant urinary incontinence commonly results in a change in clinical diagnosis.
